Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
ApexOnco Front Page
Recent articles
3 July 2025
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
2 April 2025
Chengdu Kanghong's KH815 enters human testing this month.
2 April 2025
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
1 April 2025
A biliary tract cancer trial hits on response rate, but survival data will be key.
1 April 2025
AACR approaches, along with ASCO abstract titles.
31 March 2025
Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.
31 March 2025
As the non-muscle invasive space is carved up, Aura tries to seize part of it.